Blockchain Registration Transaction Record

Soligenix Targets Psoriasis with New Therapy SGX302

Soligenix, Inc. is tackling psoriasis with SGX302, a new therapy utilizing photodynamic light therapy and synthetic hypericin. With promising results in clinical studies, this innovative approach offers hope for millions worldwide suffering from this chronic skin condition.

This news matters because psoriasis is a widespread condition that can significantly impact a patient's quality of life. Soligenix's innovative approach with SGX302 offers hope for those suffering from mild-to-moderate psoriasis, providing a potentially effective treatment option. The success of this therapy could lead to improved outcomes for patients and establish Soligenix as a key player in the treatment of rare diseases.